(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Russia provided Iran with list of Israeli energy targets, Ukrainian intelligence finds - 2Rebecca Gayheart on her 'very complicated' relationship with Eric Dane: 'I am always going to want the best for him'
- 3The most effective method to Pick the Right Material Organization: Your Definitive Aide
- 4Israel strikes south Lebanon after first direct talks in decades
- 5What to know about King Charles III's cancer treatment and his message to the public
- Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- Guinea-Bissau's coup called a 'sham' by West African political figures
- Vote in favor of Your Number one BWM Vehicles
- Everything to know about NASA's moon mission launching this week
- Careful Connections: Building Association and Trust
- Jill Hennessy was a '90s TV staple. Now she's in her fearless era.
- How comfort foods trigger pleasure in our brains
- Unpaid caregiving work can feel small and personal, but that doesn’t take away its ethical value
- Picking the Right Pot for Your Plants: An Aide for Plant Devotees
